Top

Published in:

01-02-2013 | Thoracic Oncology

The Survival Impact of XPA and XPC Genetic Polymorphisms on Patients with Esophageal Squamous Cell Carcinoma

Authors: Pei-Wen Yang, PhD, Ching-Yueh Hsieh, MS, Fang-Tzu Kuo, BS, Pei-Ming Huang, MD, Hsao-Hsun Hsu, MD, PhD, Shuenn-Wen Kuo, MD, Jin-Shing Chen, MD, PhD, Jang-Ming Lee, MD, PhD

Published in: Annals of Surgical Oncology | Issue 2/2013

Abstract

Background

The purpose of this study was to investigate the association between survival outcome of esophageal cancer patients and the genetic variants in xeroderma pigmentosum groups A (XPA) and C (XPC), 2 important molecules in the nucleotide excision pathway for DNA repair.

Methods

A total of 501 patients with a diagnosis of esophageal squamous cell carcinoma (ESCC) were enrolled in the study. The genetic variants of XPA in 5′UTR and those of XPC at exon 15 K939Q were analyzed with the TaqMan assay from the genomic DNA of peripheral leukocytes and correlated to the posttreatment survival outcome.

Results

Patients with XPA 5′UTR A/G and XPC K939Q C/C genotypes were found to be imposed with a higher risk of mortality after treatment compared with patients with wild-type homozygous genotypes [adjusted HR (95 % CI) of death being 1.36 (1.06–1.74) and 1.34 (0.97–1.83), respectively]. Cox’s multivariate analysis detected a statistically significant increased trend in risk of mortality with the accumulation of any of these 2 unfavorable genotypes compared with patients with other genotypes [adjusted HR (95 % CI) = 1.29 (1.08–1.53), P = .005]. The effect was more pronounced in the population treated with esophagectomy (P = .023) and undergoing concurrent neoadjuvant chemoradiotherapy (CCRT) (P = .002).

Conclusions

The hereditary genetic variants in XPA and XPC can serve as independent predictors of the clinical outcome of patients with ESCC, especially in those who are treated with esophagectomy and undergo chemoradiation.

Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med. 2003;349:2241–52.PubMedCrossRef

Melis M, Weber JM, McLoughlin JM, Siegel EM, Hoffe S, Shridhar R, et al. An elevated body mass index does not reduce survival after esophagectomy for cancer. Ann Surg Oncol. 2011;18:824–831.PubMedCrossRef

Allum WH, Stenning SP, Bancewicz J, Clark PI, Langley RE. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol. 2009;27:5062–7.PubMedCrossRef

Hsu PK, Wu YC, Chou TY, Huang CS, Hsu WH. Comparison of the 6th and 7th editions of the American Joint Committee on Cancer tumor-node-metastasis staging system in patients with resected esophageal carcinoma. Ann Thorac Surg. 2010;89:1024–31.PubMedCrossRef

Morgan MA, Lewis WG, Casbard A, Roberts SA, Adams R, Clark GW, et al. Stage-for-stage comparison of definitive chemoradiotherapy, surgery alone and neoadjuvant chemotherapy for oesophageal carcinoma. Br J Surg. 2009;96:1300–7.PubMedCrossRef

Abate E, DeMeester SR, Zehetner J, Oezcelik A, Ayazi S, Costales J, et al. Recurrence after esophagectomy for adenocarcinoma: defining optimal follow-up intervals and testing. J Am Coll Surg. 2010;210:428–35.PubMedCrossRef

Abrams JA, Buono DL, Strauss J, McBride RB, Hershman DL, Neugut AI. Esophagectomy compared with chemoradiation for early stage esophageal cancer in the elderly. Cancer. 2009;115:4924–33.PubMedCrossRef

Das A, Singh V, Fleischer DE, Sharma VK. A comparison of endoscopic treatment and surgery in early esophageal cancer: an analysis of surveillance epidemiology and end results data. Am J Gastroenterol. 2008;103:1340–5.PubMedCrossRef

Suzuki A, Xiao L, Hayashi Y, Macapinlac HA, Welsh J, Lin SH, et al. Prognostic significance of baseline positron emission tomography and importance of clinical complete response in patients with esophageal or gastroesophageal junction cancer treated with definitive chemoradiotherapy. Cancer. 2011;4823–33.

10.

Costa RM, Chigancas V, Galhardo Rda S, Carvalho H, Menck CF. The eukaryotic nucleotide excision repair pathway. Biochimie. 2003;85:1083–99.PubMedCrossRef

11.

Gillet LC, Scharer OD. Molecular mechanisms of mammalian global genome nucleotide excision repair. Chem Rev. 2006;106:253–76.PubMedCrossRef

12.

Martin LP, Hamilton TC, Schilder RJ. Platinum resistance: the role of DNA repair pathways. Clin Cancer Res. 2008;14:1291–5.PubMedCrossRef

13.

Vens C, Begg AC. Targeting base excision repair as a sensitization strategy in radiotherapy. Semin Radiat Oncol. 2010;20:241–9.PubMedCrossRef

14.

Carden CP, Yap TA, Kaye SB. PARP inhibition: targeting the Achilles’ heel of DNA repair to treat germline and sporadic ovarian cancers. Curr Opin Oncol. 2010;22:473–80.PubMedCrossRef

15.

Sarasin A, Dessen P. DNA repair pathways and human metastatic malignant melanoma. Curr Mol Med. 2010;10:413–8.PubMedCrossRef

16.

Li L, Peterson C, Legerski R. Sequence of the mouse XPC cDNA and genomic structure of the human XPC gene. Nucleic Acids Res. 1996;24:1026–8.PubMedCrossRef

17.

Despras E, Pfeiffer P, Salles B, Calsou P, Kuhfittig-Kulle S, Angulo JF, et al. Long-term XPC silencing reduces DNA double-strand break repair. Cancer Res. 2007;67:2526–34.PubMedCrossRef

18.

Shimizu Y, Iwai S, Hanaoka F, Sugasawa K. Xeroderma pigmentosum group C protein interacts physically and functionally with thymine DNA glycosylase. EMBO J. 2003;22:164–73.PubMedCrossRef

19.

Vogel U, Overvad K, Wallin H, Tjonneland A, Nexo BA, Raaschou-Nielsen O. Combinations of polymorphisms in XPD, XPC and XPA in relation to risk of lung cancer. Cancer Lett. 2005;222:67–74.PubMedCrossRef

20.

Zhang L., Zhang Z, Yan W. Single nucleotide polymorphisms for DNA repair genes in breast cancer patients. Clin Chim Acta. 2005;359:150–5.PubMedCrossRef

21.

Weiss JM, Weiss NS, Ulrich CM, Doherty JA, Chen C. Nucleotide excision repair genotype and the incidence of endometrial cancer: effect of other risk factors on the association. Gynecol Oncol. 2006;103:891–6.PubMedCrossRef

22.

Guo W, Zhou RM, Wan LL, Wang N, Li Y, Zhang XJ, et al. Polymorphisms of the DNA repair gene xeroderma pigmentosum groups A and C and risk of esophageal squamous cell carcinoma in a population of high incidence region of North China. J Cancer Res Clin Oncol. 2008;134:263–70.PubMedCrossRef

23.

Li Z, Musich PR, Zou Y. Differential DNA damage responses in p53 proficient and deficient cells: cisplatin-induced nuclear import of XPA is independent of ATR checkpoint in p53-deficient lung cancer cells. Int J Biochem Mol Biol. 2011;2:138–145.PubMed

24.

Butkiewicz D, Popanda O, Risch A, Edler L, Dienemann H, Schulz V, et al. Association between the risk for lung adenocarcinoma and a (-4) G-to-A polymorphism in the XPA gene. Cancer Epidemiol Biomarkers Prev. 2004;13:2242–6.PubMed

25.

Dong Z, Guo W, Zhou R, Wan L, Li Y, Wang N, et al. Polymorphisms of the DNA repair gene XPA and XPC and its correlation with gastric cardiac adenocarcinoma in a high incidence population in North China. J Clin Gastroenterol. 2008;42:910–5.PubMedCrossRef

26.

Qian B, Zhang H, Zhang L, Zhou X, Yu H, Chen K. Association of genetic polymorphisms in DNA repair pathway genes with non-small cell lung cancer risk. Lung Cancer. 2011;73:138–46.PubMedCrossRef

27.

Miller KL, Karagas MR, Kraft P, Hunter DJ, Catalano PJ, Byler SH, et al. XPA, haplotypes, and risk of basal and squamous cell carcinoma. Carcinogenesis. 2006;27:1670–5.PubMedCrossRef

28.

Sugimura T, Kumimoto H, Tohnai I, Fukui T, Matsuo K, Tsurusako S, et al. Gene-environment interaction involved in oral carcinogenesis: molecular epidemiological study for metabolic and DNA repair gene polymorphisms. J Oral Pathol Med. 2006;35:11–8.PubMedCrossRef

29.

Pan J, Lin J, Izzo JG, Liu Y, Xing J, Huang M, et al. Genetic susceptibility to esophageal cancer: the role of the nucleotide excision repair pathway. Carcinogenesis. 2009;30:785–92.PubMedCrossRef

30.

Carles J, Monzo M, Amat M, Jansa S, Artells R, Navarro A, et al. Single-nucleotide polymorphisms in base excision repair, nucleotide excision repair, and double strand break genes as markers for response to radiotherapy in patients with Stage I to II head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2006;66:1022–30.PubMedCrossRef

31.

Gu J, Zhao H, Dinney CP, Zhu Y, Leibovici D, Bermejo CE, et al. Nucleotide excision repair gene polymorphisms and recurrence after treatment for superficial bladder cancer. Clin Cancer Res. 2005;11:1408–15.PubMedCrossRef

32.

Monzo M. Moreno I, Navarro A, Ibeas R, Artells R, Gel B, et al. Single nucleotide polymorphisms in nucleotide excision repair genes XPA, XPD, XPG and ERCC1 in advanced colorectal cancer patients treated with first-line oxaliplatin/fluoropyrimidine. Oncology. 2007;72:364–70.PubMedCrossRef

33.

Lee JM, Yang PW, Yang SY, Chuang TH, Tung EC, Chen JS, et al. Genetic variants in DNA repair predicts the survival of patients with esophageal cancer. Ann Surg. 2011;253:918–27.PubMedCrossRef

34.

Greene FL, Page DL, Fleming ID. Esophagus. In: American Joint Committee on Cancer (AJCC) Cancer Staging Manual. 6th ed. New York: Springer; 2002:167–78.

35.

Schneider PM, Baldus SE, Metzger R, Kocher M, Bongartz R, Bollschweiler E, et al. Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification. Ann Surg. 2005;242:684–92.PubMedCrossRef

36.

Wu TT, Chirieac LR, Abraham SC, Krasinskas AM, Wang H, Rashid A, et al. Excellent interobserver agreement on grading the extent of residual carcinoma after preoperative chemoradiation in esophageal and esophagogastric junction carcinoma: a reliable predictor for patient outcome. Am J Surg Pathol. 2007;31:58–64.PubMedCrossRef

37.

Monzo M, Brunet S, Urbano-Ispizua A, Navarro A, Perea G, Esteve J, et al. Genomic polymorphisms provide prognostic information in intermediate-risk acute myeloblastic leukemia. Blood. 2006;107:4871–9.PubMedCrossRef

38.

Stoehlmacher J, Park DJ, Zhang W, Yang D, Groshen S, Zahedy S, et al. A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer. 2004;91:344–54.PubMed

39.

Heidenreich E, Eisler H, Lengheimer T, Dorninger P, Steinboeck F. A mutation-promotive role of nucleotide excision repair in cell cycle-arrested cell populations following UV irradiation. DNA Repair (Amst). 2010;9:96–100.CrossRef

40.

Lomonaco SL, Xu XS, Wang G. The role of Bcl-x(L) protein in nucleotide excision repair-facilitated cell protection against cisplatin-induced apoptosis. DNA Cell Biol. 2009;28:285–94.PubMedCrossRef

41.

Wu X, Shell SM, Yang Z, Zou Y. Phosphorylation of nucleotide excision repair factor xeroderma pigmentosum group A by ataxia telangiectasia mutated and Rad3-related-dependent checkpoint pathway promotes cell survival in response to UV irradiation. Cancer Res. 2006;66:2997–3005.PubMedCrossRef

42.

Zhu Y, Yang H, Chen Q, Lin J, Grossman HB, Dinney CP, et al. Modulation of DNA damage/DNA repair capacity by XPC polymorphisms. DNA Repair (Amst). 2008;7:141–8.CrossRef

43.

Laczmanska I, Gil J, Karpinski P, Stembalska A, Trusewicz A, Pesz K, et al. Polymorphism in nucleotide excision repair gene XPC correlates with bleomycin-induced chromosomal aberrations. Environ Mol Mutagen. 2007;48:666–71.PubMedCrossRef

44.

Stahl M. Is there any role for surgery in the multidisciplinary treatment of esophageal cancer? Ann Oncol. 2010;21 Suppl 7:vii283–5.

45.

Lee PC, Mirza FM, Port JL, Stiles BM, Paul S, Christos P, et al. Predictors of recurrence and disease-free survival in patients with completely resected esophageal carcinoma. J Thorac Cardiovasc Surg. 2011;141:1196–206.PubMedCrossRef

46.

Bosset JF, Gignoux M, Triboulet JP, Tiret E, Mantion G, Elias D, et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med. 1997;337:161–7.PubMedCrossRef

47.

Steyerberg EW, Neville BA, Koppert LB, Lemmens VE, Tilanus HW, Coebergh JW, et al. Surgical mortality in patients with esophageal cancer: development and validation of a simple risk score. J Clin Oncol. 2006;24:4277–84.PubMedCrossRef

48.

Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TP. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med. 1996;335:462–7.PubMedCrossRef

49.

Ott K, Rachakonda PS, Panzram B, Keller G, Lordick F, Becker K, et al. DNA repair gene and MTHFR gene polymorphisms as prognostic markers in locally advanced adenocarcinoma of the esophagus or stomach treated with cisplatin and 5-fluorouracil-based neoadjuvant chemotherapy. Ann Surg Oncol. 2011;18:2688–98.PubMedCrossRef

50.

Gurubhagavatula S, Liu G, Park S, Zhou W, Su L, Wain JC, et al. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol. 2004;22:2594–601.PubMedCrossRef

51.

Sakano S, Wada T, Matsumoto H, Sugiyama S, Inoue R, Eguchi S, et al. Single nucleotide polymorphisms in DNA repair genes might be prognostic factors in muscle-invasive bladder cancer patients treated with chemoradiotherapy. Br J Cancer. 2006;95:561–70.PubMedCrossRef

Title: The Survival Impact of XPA and XPC Genetic Polymorphisms on Patients with Esophageal Squamous Cell Carcinoma
Authors: Pei-Wen Yang, PhD
Ching-Yueh Hsieh, MS
Fang-Tzu Kuo, BS
Pei-Ming Huang, MD
Hsao-Hsun Hsu, MD, PhD
Shuenn-Wen Kuo, MD
Jin-Shing Chen, MD, PhD
Jang-Ming Lee, MD, PhD
Publication date: 01-02-2013
Publisher: Springer-Verlag
Published in: Annals of Surgical Oncology / Issue 2/2013
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-012-2622-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The Survival Impact of XPA and XPC Genetic Polymorphisms on Patients with Esophageal Squamous Cell Carcinoma

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2013

Quality of Care Indicators for the Surgical Treatment of Gastric Cancer: A Systematic Review

Influence of Comorbidity and Age on 1-, 2-, and 3-Month Postoperative Mortality Rates in Gastrointestinal Cancer Patients

Morbidity of Staged Proctectomy After Hepatectomy for Colorectal Cancer: A Matched Case–Control Analysis

A Novel Nomogram for Peritoneal Mesothelioma Predicts Survival

Intraoperative Diagnosis Using Sentinel Node Biopsy with Indocyanine Green Dye in Gastric Cancer Surgery: An Institutional Trial by Experienced Surgeons

High Expression of Patched Homolog-1 Messenger RNA and Glioma-Associated Oncogene-1 Messenger RNA of Sonic Hedgehog Signaling Pathway Indicates a Risk of Postresection Recurrence of Hepatocellular Carcinoma